Elsa Ramon is the weekend evening anchor and weekday reporter for CBS2/KCAL9 and has received four Emmy nominations for her exceptional work in newscasting. Elsa graduated from the University of California, Irvine with a B.A. in English Literature and is a proud Anteater in support of Alzheimer’s disease research at UCI MIND. Elsa recently participated in a behind-the-scenes tour of the UCI MIND research labs seeing for herself the dedication and determination of each and every faculty, staff, and student involved. Elsa’s grandmother suffers from Alzheimer’s disease, which compels and excites her to share with her southern California viewers the exciting…

Have questions about healthy brain aging, memory loss, or Alzheimer's disease research? Come to an open forum Q&A session on November 3 at The Covington in Aliso Viejo from 5:30-7:30 pm. UCI MIND is bringing a panel of experts to you at no cost. Hope to see you there! Click here to register online or call Kirsten Klein at (949) 824-9475. http://askucimind.eventbrite.com                    

Reserve tickets today for the 7th Annual UCI MIND Gala, A December to Remember, on December 3rd at the Balboa Bay Resort in Newport Beach! Toast the holidays with an elegant evening of dining, dancing, and philanthropy that will have a lasting impact. All proceeds will support Alzheimer's research at UCI MIND, OC's only state and federally funded Alzheimer's Disease Research Center. Tickets & Event Information>                  

"UCI MIND takes multipronged approach to finding preventions, cures in effort to avert baby-boom crisis..."                    

Click to view a message from Dr. Grill!

September 21, 2016, is World Alzheimer's Day!  Learn more about Alzheimer's disease on our website and help spread the word about the exciting happenings in Alzheimer's disease research at UCI MIND.

Research is the key to finding treatments and cures for Alzheimer’s disease and other urgent health problems. If you or someone you know is interested in helping researchers at UCI find cures faster, check out our new online potential participant registry, Consent 2 Contact (C2C)!  c2c.uci.edu    

September 1, 2016 Nature   A paper published August 31 in Nature, describes that Biogen Idec’s candidate treatment, aducanumab, reduced amyloid-β in the brains of patients with early-stage Alzheimer’s disease. Patients receiving the highest doses of the medicine in the Phase IB trial had the largest reductions in brain amyloid and also declined the least in clinical assessments.  These are promising results that will require replication in larger clinical trials, which have recently launched, including at UCI MIND. Read the Nature news article about the study here.